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entitled ''Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA Identical-sibling allogeneic hematopoietic cell transplantation in AML and MDS''.
In this issue of Bone Marrow Transplantation, De La Serna et al. 1 analyzed the outcome of a multicenter and single-arm study of patients with primary or secondary AML or MDS conditioned with 4 days of once-daily fludarabine (Flu, 40 mg/m 2 /day) in combination with once-daily busulfan (Bu, 3.2 mg/kg or about 130 mg/m 2 ) to a total Bu dose of 12.8 mg/kg. The patients received an allogeneic stem cell transplant using HLA-matched sibling donors. They concluded that this 4-day schedule was associated with low non-relapse mortality and high level of safety, but the GvHD incidence still merits further attention.
A major strength of this report is that it addresses a clearly delineated problem and confines the investigation to a fairly homogenous patient population with overall poor prognosis for survival without transplantation.
Previous investigators have concluded that more intensive conditioning therapy in general improves disease control, but not overall survival, 2, 3 or that neither survival nor disease control is improved, depending on what conditioning regimens were utilized. 4, 5 Thus, there is a controversy about the role and contribution of the conditioning regimen for long-term progression-free and overall survival. This should not be surprising. Potential biases in clinical research protocols include variability in patient samples, disease stage, comorbidities and bias in patient selection for treatment. In addition, the treating physician's perception of what a patient might tolerate, or may need to secure disease control and engraftment, unavoidably influences treatment selection.
In the current report and like what has been described in other recent publications, the investigators refer to their regimen as 'the BuFlu regimen'. Although it is true that the drugs are the same as those used in many other published studies, it is still important to emphasize that there is no specific BuFlu regimen; the two agents can be administered in multiple ways, including sequentially starting with one or the other drug with or without a rest day before initiating the second drug, and alternatively administering both drugs on the same days, starting with one or the other agent. Alternatively, one could also start with Bu for 2 (or 3) days, after which Flu is added, similar to what is done in the classic Bu-cyclophosphamide (Cy) regimen(s). Finally, Bu can be administered every 6 (or 12) h or only once daily. These considerations are not only of theoretical interest. The original investigations of the importance of timing and sequencing of the different agents in a nucleoside analog-alkylating agent combination were performed in carefully controlled model systems, where the resulting cytotoxicity could be assayed partly as a function of the administration schedule; thus, Yamauchi et al. 6 demonstrated that varying the sequence of the drugs can yield synergistic, additive or even antagonistic cell kill. Preexposure of lymphocytes from CLL patients to Flu and/or clofarabine prior to addition of 4-hydroperoxycyclophosphamide (4-HC) synergistically inhibited DNA-damage repair initiated by the 4-HC exposure. These findings were later confirmed using Bu as a prototype DNA-alkylating agent. 7 Based on recent publications, there is reason to believe that the sequence and timing of the respective drug may also influence outcome in the clinical setting. The concomitant use of Flu and Bu in a 4-5-day combination yields very similar outcomes, [8] [9] [10] [11] [12] [13] [14] [15] especially in high-risk patient subpopulations. In contrast, investigators who use sequential administration of the two drugs reported similar low non-relapse mortality, but possibly a higher post-transplant relapse risk, especially in high-risk patients. 16 In addition, exposure to the alkylating agent before adding Flu may lead to antagonistic cytotoxicity, that is, protection of the marrow and malignant cell populations from toxicity (extrapolated from refs 6,7). Clinically, this may translate into an unexpectedly high graft failure rate and lack of disease control, as was reported in a randomized study comparing Bu-Cy2 with 'Bu-Flu'. 17 Finally, the use of 1 vs 2 rest days before infusion of the grafted cells may, to some extent, also influence outcome, as Flu has a quite long half-life (410 h), and after 1 rest day, the systemic concentration of activated Flu is high enough that it may impact the establishment of proper graft function, especially if a weak or highly HLA-disparate graft is used. 18 In summary, the reduced-toxicity nucleoside analog-Bu platform concept has contributed to greatly improved safety of both myeloablative and reduced-intensity conditioning therapy as demonstrated by De la Serna et al. 1 However, we should recognize that not all conditioning programs are created equal even if different investigators seemingly use the same cytotoxic drugs; sequence and timing of the different agents coupled with interpatient variability in metabolic drug handling lead to variable pharmacokinetics and pharmacodynamics. In addition, molecular interactions not only between the different cytotoxic agents but also with concomitantly used supportive care agents will affect cellular signaling pathways and influence clinical treatment outcome. All of these aspects will need to be considered when
